FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare
About | Sample | Privacy

BMS, Repligen settle Orencia fight

Four companies, two disputed patents, two multimillion-dollar settlements.

Repligen and Bristol-Myers Squibb buried the hatchet over Orencia, the rheumatoid arthritis treatment that's been subject to a patent dispute between the two companies. Bristol-Myers will pay $5 million plus royalties on U.S. net sales of Orencia to settle the disagreement. Repligen expects its first years' receipts from BMS to be around $30 million.

Meanwhile, Depomed will get about $10 million in payments and royalties in settlement of a patent infringement case against Ivax Corp. and its parent company, Teva Pharmaceuticals. The drug in question was the diabetes treatment Glucophage XR.

- check out the Orencia agreement
- see the Depomed news in the San Jose Business Journal

Related Articles:
NICE snubs Orencia, picks 3 rivals. Report
Regulatory panel gives BMS' Orencia unanimous approval. Report

More stories about Orencia   Depomed   BMS   Teva Pharmaceutical   rheumatoid arthritis   Repligen  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 82 + 17?
To combat spam, please solve the math question above.